Opinion

Video

Overview of Abiraterone and the Differences Between Formulations

Author(s):

Gautam Jayram, MD,Christopher Pieczonka, MD

This discussion provides an overview of abiraterone and the key differences between micronized and non-micronized formulations, including considerations for choosing between the two formulations.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      • Please provide a brief overview of abiraterone and the key differences between micronized and non-micronized formulations.
      • How do you approach deciding between the 2 formulations (micronized vs non-micronized)?

      Related Videos
      NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
      NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
      1 expert is featured in this series.
      BRCA Mutations in mHSPC: Impact on Therapy Selection
      1 expert is featured in this series.
      Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
      Defining and Managing BCG-Unresponsive NMIBC
      Defining and Managing BCG-Unresponsive NMIBC
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      1 expert is featured in this series.
      Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
      1 expert is featured in this series.
      The Incidence of Prostate Cancer and Risk of Progression in Black Men
      2 experts are featured in this series.
      The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
      2 experts are featured in this series.
      The Evolvement of Imaging in ccRCC
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Related Content
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
      May 6th 2025

      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

      Hannah Clarke
      Initial study results may be available as soon as the first half of 2026.
      Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
      May 2nd 2025

      Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

      Amy M. Pearlman, MD
      Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      ARANOTE substudy highlights benefits of darolutamide in Black men
      April 28th 2025

      ARANOTE substudy highlights benefits of darolutamide in Black men

      Benjamin P. Saylor
      The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
      © 2025 MJH Life Sciences

      All rights reserved.